| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| Harvest Oriental | 1,981,700 | 2.52% | 2.52% | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO saw an extreme oversubscription ratio of 3165.1x, indicating intense investor enthusiasm. Overall hit rate was a mere 6.82%, meaning only a small fraction of applicants received allocations. The offer price was fixed at HKD 86.4 with no disclosed range, and the reallocation was triggered, suggesting strong institutional demand as well. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The A-tail (50,000 lots) expected allocation was 0.3272 lots, only marginally below the B-head (60,000 lots) at 0.3482 lots. This near-parity indicates severe inefficiency, as the additional 10,000 lots yield a negligible increment. Given the higher capital and broker fees for B-head, the A-tail tier appears more cost-effective, though actual broker fee structures vary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Mainland investors accounted for 63.5% of successful applicants, signaling robust cross-border demand for this biopharmaceutical IPO. The gender split was 63% male and 37% female, and the average age was 43.2, reflecting a slightly older and male-skewed investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Haixi Pharma (02637): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

